azetidyl-2-carboxylic acid has been researched along with Disease Models, Animal in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chen, J; Dong, Q; Gao, Y; Jiao, L; Qian, Y; Qiu, L; Sun, Y; Wang, H; Wu, Y; Zhai, W; Zhao, W; Zheng, WV; Zhou, X | 1 |
| Hirata, Y; Kitagawa, T; Kurobe, H; Matsuoka, Y; Maxfield, MW; Sata, M; Sugasawa, N | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Ikeda, Y; Kono, S; Kurata, T; Liu, W; Omote, Y; Yamashita, T | 1 |
| Fukumoto, Y; Ito, K; Nawata, J; Onoue, N; Shimokawa, H; Sugimura, K; Tada, T; Wang, H; Zhulanqiqige, D | 1 |
| Aoyagi, K; Hirayama, A; Koyama, A; Nagase, S; Oteki, T; Ueda, A | 1 |
| Araki, S; Hirooka, Y; Kishi, T; Koga, Y; Konno, S; Sunagawa, K | 1 |
| Abe, K; Deguchi, K; Kamiya, T; Nagotani, S; Yamashita, T | 1 |
| Hosoya, M; Ohashi, J; Sawada, A; Shimokawa, H; Takaki, A | 1 |
| Amirghofran, Z; Bagheri, M; Jahromi, BM; Mirkhani, H; Noorafshan, A; Solhjou, Z; Zamani, A | 1 |
| Horiguchi, N; Ichikawa, T; Izumi, T; Kakizaki, S; Kishimoto, K; Mori, M; Ohyama, T; Sato, K; Takagi, H; Yamazaki, Y | 1 |
| Fujimoto, S; Kashihara, N; Nagasu, H; Sasaki, T; Satoh, M; Tomita, N | 1 |
| Hirooka, Y; Kishi, T; Ogawa, K; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K | 1 |
| Fujisawa, M; Koike, H; Matsuoka, Y; Ueno, K; Yorikane, R | 1 |
| Horiuchi, M; Ide, A; Iwai, M; Li, JM; Li, Z; Min, LJ; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Chen, R; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Mogi, M; Tomochika, H; Tomono, Y | 1 |
| Egashira, K; Gang, Z; Iwata, E; Miyagawa, M; Nakano, K; Ohtani, K; Sunagawa, K | 1 |
| Akashi, H; Aoyagi, S; Hiromatsu, S; Kato, S; Yokokura, H | 1 |
| Guo, Q; Ito, O; Kanazawa, M; Kohzuki, M; Kurosawa, H; Minami, N; Mori, N; Nagasaka, M | 1 |
1 review(s) available for azetidyl-2-carboxylic acid and Disease Models, Animal
| Article | Year |
|---|---|
Gene and stem cell therapy in ischemic stroke.
Topics: Animals; Antioxidants; Azetidinecarboxylic Acid; Biliverdine; Brain Ischemia; Dihydropyridines; Disease Models, Animal; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Humans; Models, Biological; Neuroprotective Agents; Stem Cell Transplantation | 2009 |
19 other study(ies) available for azetidyl-2-carboxylic acid and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPĪ± and TIGIT/PVR Pathways for Cancer Immuno-Therapy.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; CD47 Antigen; Cell Line, Tumor; Cricetinae; Dihydropyridines; Disease Models, Animal; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Immunotherapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplasms; Receptors, Immunologic; Receptors, Virus; T-Lymphocytes | 2021 |
Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
Topics: Aminopropionitrile; Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Disease Progression; Inflammation Mediators; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Sirtuin 1; Time Factors; Tumor Necrosis Factor-alpha | 2013 |
Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
Topics: Age Factors; Animals; Azetidinecarboxylic Acid; Blood Pressure; Brain Injuries; Chemokine CCL2; Collagen Type IV; Dihydropyridines; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Heart Rate; Imidazoles; Laser-Doppler Flowmetry; Male; Matrix Metalloproteinase 9; Motor Activity; Oxidative Stress; Rats; Rats, Inbred SHR; Stroke; Tetrazoles | 2014 |
Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Calcium Signaling; Cell Movement; Cells, Cultured; Dihydropyridines; Disease Models, Animal; Equipment and Supplies; Estrenes; Hypertension; Imidazoles; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Muscle, Smooth, Vascular; Oxazoles; Pyrrolidinones; Rats; Rats, Wistar; Signal Transduction; Tetrazoles; Type C Phospholipases | 2008 |
In vivo imaging of renal redox status during azelnidipine treatment.
Topics: Animals; Antioxidants; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Creatinine; Dihydropyridines; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Hypertension, Renal; Kidney; Male; Mice; Mice, Inbred ICR; Oxidation-Reduction; Oxidative Stress | 2008 |
Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Antioxidants; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Heart Rate; Hydralazine; Hypertension; Male; Medulla Oblongata; NADPH Oxidases; Norepinephrine; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System; Thiobarbituric Acid Reactive Substances | 2008 |
Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Azetidinecarboxylic Acid; Biological Factors; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Signal Transduction; Streptozocin; Tetrazoles; Vasodilation | 2010 |
Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Male; Nitric Oxide; Nitrites; Rats; Skin; Streptozocin; Wound Healing | 2011 |
Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.
Topics: Angiotensin II; Animals; Antioxidants; Azetidinecarboxylic Acid; Calcium; Calcium Channel Blockers; Carbon Tetrachloride; Cell Line; Cell Survival; Collagen Type I; Collagen Type I, alpha 1 Chain; Dihydropyridines; Disease Models, Animal; Gene Expression Regulation; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Reactive Oxygen Species; RNA, Messenger; Thioacetamide; Transforming Growth Factor beta1 | 2012 |
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Topics: Amlodipine; Animals; Arterioles; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Heart Rate; Kidney Diseases; Kidney Glomerulus; Male; Rats; Rats, Inbred Dahl; Sympathectomy; Sympathetic Nervous System | 2012 |
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Oxidative Stress; Rats; Rats, Inbred SHR; Tetrazoles | 2012 |
The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
Topics: Administration, Oral; Amlodipine; Angina Pectoris; Animals; Arginine Vasopressin; Azetidinecarboxylic Acid; Blood Pressure; Calcium; Calcium Channel Blockers; Coronary Vessels; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Male; Myocardium; Oxygen Consumption; Rats; Swine; Time Factors; Vasoconstriction | 2013 |
Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Cells, Cultured; Dihydropyridines; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imidazoles; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NADPH Oxidases; Olmesartan Medoxomil; Oxidative Stress; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Superoxides; Tetrazoles; Time Factors | 2005 |
The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Circulation; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Imidazoles; Male; Mice; Mice, Inbred C57BL; Tetrazoles | 2006 |
Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Macaca fascicularis; Male; Mice; Mice, Knockout; Platelet-Derived Growth Factor; Random Allocation; Tunica Intima | 2008 |
Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Disease Progression; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Rats; Rats, Wistar | 2007 |
Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Combined Modality Therapy; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Heart Rate; Hypertension; Imidazoles; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Physical Conditioning, Animal; Rats; Rats, Inbred SHR; Regression Analysis; Sympathetic Nervous System; Tetrazoles | 2008 |